Corgenix, BG combine in study partnership
This article was originally published in Clinica
Executive Summary
In vitro diagnostics company Corgenix Medical (Denver, Colorado) is set to make its AtherOx line of products available for studies conducted by life sciences firm BG Medicine, in a bid to help predict near-term risk of first myocardial infarction. The two firms have come together in a collaboration which will see Corgenix provide its IgG Anti-AtherOx, Anti-AtherOx IgM and AtherOx kits for BG’s studies of atherosclerosis and arterial lesions. Additionally, Corgenix said that it may use the data from the studies for its own regulatory and commercialisation purposes, in exchange for certain considerations. Financial terms of the partnership were not revealed.
You may also be interested in...
Alere aided by professional diagnostics sales in fourth quarter
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra and Stout to work on expandable interbody device
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe eyes portfolio expansion to help boost molecular diagnostics credentials
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals